Skip to main content

Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer



To evaluate adherence to abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).


In an observational prospective cohort study, we monitored patients with mCRPC for their adherence to abiraterone or enzalutamide in the pre- or post-chemotherapy setting.


Fifty-eight patients with median age of 76 years (range 56–94), age-adjusted Charlson comorbidity score of 10 (range, 4–15), and geriatric G8 score of 14 (range, 6–17) were enrolled. Twenty-two (38%) patients were treated with abiraterone and 36 (62%) with enzalutamide, while forty-two (72%) were in the pre-chemotherapy setting. Forty-seven patients (81%) had a caregiver. Based on the pill counting, a non-adherence rate of 4.8% and 6.2% was observed for the whole period and the first 3 months, respectively, without a statistically significant difference between abiraterone and enzalutamide cohorts. A lower non-adherence rate (1.3%) was reported by patients during the whole period, mainly due to a misperception (77%) and forgetfulness (19%). Non-adherence rate to the fulfilling of the clinical diary was 38% for the whole period. Non-adherence in the whole period was related to the radiological response (p = 0.03) and geriatric G8 score (p = 0.005). By the receiver operating characteristic (ROC) curve based on the radiological response, non-adherence cut-off was 1.87% (p = 0.04). By this non-adherence cut-off, the G8 cut-off was 14.75 (p = 0.0003).


Non-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients’ frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS (2019) Managing nonmetastatic castration-resistant prostate cancer. Eur Urol 75(2):285–293.

    Article  PubMed  Google Scholar 

  2. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 75(1):88–99.

    Article  PubMed  Google Scholar 

  3. Banna GL, Collova E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferrau F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36(8):595–605.

    Article  PubMed  Google Scholar 

  4. Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, Pirl WF, Temel JS, Greer JA (2017) Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract 13(5):e474–e485.

    Article  PubMed  Google Scholar 

  5. Gebbia V, Bellavia M, Banna GL, Russo P, Ferrau F, Tralongo P, Borsellino N (2013) Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clinical lung cancer 14(4):390–398.

    Article  CAS  PubMed  Google Scholar 

  6. Nguyen TM, La Caze A, Cottrell N (2014) What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol 77(3):427–445.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342(8878):1032–1036.

    Article  CAS  PubMed  Google Scholar 

  8. Devons CA (2002) Comprehensive geriatric assessment: making the most of the aging years. Curr Opin Clin Nutr Metab Care 5(1):19–24

    Article  Google Scholar 

  9. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

    Article  CAS  Google Scholar 

  10. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251

    Article  CAS  Google Scholar 

  11. Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safren SA, Pirl WF (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):354–376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cleemput I, Dobbels F (2007) Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date. PharmacoEconomics 25(4):269–286.

    Article  PubMed  Google Scholar 

  13. Wilcoxon F (1945) Individual comparisons by ranking methods. Biom Bull 1(6):80–83.

    Article  Google Scholar 

  14. Fisher RA (1922) On the interpretation of χ<sup>2</sup> from contingency tables, and the calculation of P. J R Stat Soc 85(1):87–94.

    Article  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247.

    Article  CAS  Google Scholar 

  16. Kaplan EL, Meier P (1958) Nonparamentric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481

    Article  Google Scholar 

  17. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50(3):163–170

    CAS  PubMed  Google Scholar 

  18. Fieller EC, Hartley HO, Pearson ES (1957) Tests for rank correlation coefficients. I Biometrika 44(3–4):470–481.

    Article  Google Scholar 

  19. Fawcett T (2006) An introduction to ROC analysis. Pattern Recogn Lett 27(8):861–874.

    Article  Google Scholar 

  20. Unni EJ, Farris KB (2011) Unintentional non-adherence and belief in medicines in older adults. Patient Educ Couns 83(2):265–268.

    Article  PubMed  Google Scholar 

  21. Schneider SM, Hess K, Gosselin T (2011) Interventions to promote adherence with oral agents. Semin Oncol Nurs 27(2):133–141.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Bruijnen CP, van Harten-Krouwel DG, Koldenhof JJ, Emmelot-Vonk MH, Witteveen PO Predictive value of each geriatric assessment domain for older patients with cancer: a systematic review. J Geriatr Oncolo.

  23. Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. JNCI: Journal of the National Cancer Institute 94(9):652–661.

    Article  PubMed  Google Scholar 

  24. Gornas M, Szczylik C (2010) Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process? Eur J Cancer Care (Engl) 19(1):131–136.

    Article  CAS  Google Scholar 

  25. Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, Coolbrandt A, Biganzoli L (2017) Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev 57:58–66.

    Article  PubMed  Google Scholar 

  26. Glajchen M (2004) The emerging role and needs of family caregivers in cancer care. J Support Oncol 2(2):145–155

    PubMed  Google Scholar 

  27. O'Quin KE, Semalulu T, Orom H (2015) Elder and caregiver solutions to improve medication adherence. Health Educ Res 30(2):323–335.

    Article  CAS  PubMed  Google Scholar 

  28. Costa E, Giardini A, Savin M, Menditto E, Lehane E, Laosa O, Pecorelli S, Monaco A, Marengoni A (2015) Interventional tools to improve medication adherence: review of literature. Patient Prefer Adherence 9:1303–1314.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Giuseppe L. Banna.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Banna, G.L., Urzia, V., Benanti, C. et al. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Support Care Cancer 28, 4687–4695 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Adherence
  • Compliance
  • Prostate cancer
  • Abiraterone
  • Enzalutamide
  • Elderly